A Double-Blind Comparison of Efficacy of 0.1% Tacrolimus Ophthalmic Ointment and 2% Cyclosporine Eye Drop Vernal Keratoconjunctivitis (vkc)

Labcharoenwongs, P.; Durongpisitkul, W.; Dumrongkigchaiporn, P.; Jirapongsananuruk, Orathai; Visitsunthorn, Nualanong; Kosrirukvongs, Panida; Booranapong, Wipawee; Vichyanond, Pakit

doi:10.1016/j.jaci.2005.12.669

Cited by 32 publications

(70 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Male pediatric population is typically more affected than female, 1,5,13 and similar observation was noted in the present study, with male:female ratio of 2.3:1.…”

Section: Ijaimssupporting

confidence: 89%

See 1 more Smart Citation

Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis

Gupta¹,

Goyal²,

Devendra³

2016

International Journal of Advanced and Integrated Medical Sciences

View full text Add to dashboard Cite

show abstract

“…Male pediatric population is typically more affected than female, 1,5,13 and similar observation was noted in the present study, with male:female ratio of 2.3:1.…”

Section: Ijaimssupporting

confidence: 89%

“…[3][4][5] Steroids are being used as the mainstay of treatment for VKC, but a standard treatment protocol is not yet established. Steroids are very effective in controlling the acute exacerbation, but they may cause intraocular pressure elevation in steroid-responders, risk of corneal infection, and cataract.…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis

Gupta¹,

Goyal²,

Devendra³

2016

International Journal of Advanced and Integrated Medical Sciences

View full text Add to dashboard Cite

show abstract

“…The most frequent tacrolimus related adverse event was ocular irritation. A prospective double masked randomised comparative trial comparing the efficacy of 0.01% tacrolimus ointment with Cyclosporine A 2% showed that both were equally effective in the treatment of VKC 18 .…”

Section: Discussionmentioning

confidence: 99%

Study of Clinical Features and Management of Vernal Keratoconjunctivitis

Nagrale¹

2017

jmscr

View full text Add to dashboard Cite

“…T cell culture from conjunctival scraping of VKC patients yielded mainly Th2-type clones. Th2-derived cytokines such as IL-4, IL-5, IL-13, growth factors and enzymes are found in the conjunctiva of VKC patients [11]. In addition, some researchers have demonstrated the possible involvement of neural factors, sex hormones and conjunctival histaminase deficiency in the pathogenesis of the disease [2,10,11].…”

mentioning

confidence: 99%

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Keklíkçí¹,

Dursun²,

Cingü³

2014

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Vernal keratoconjunctivitis (VKC) is a chronic, bilateral inflammation of the conjunctiva that mostly affects children and young adult males. Management of VKC is primarily aimed at reducing symptoms and preventing serious vision threatening sequelae. Objectives. To assess the efficacy of topical cyclosporine A (CsA) 0.05% on the signs and symtomps in the management of VKC. Material and Methods. This is a placebo-controlled, randomized prospective study. Sixty-two patients with VKC were included in this study. Patients were randomly assigned (1 : 1) to treatment with topical 0.05% CsA eyedrops or a placebo (artificial tears) for a period of 4 weeks, 4 times daily. Ocular signs and symptoms were in all patients scored at entry and at the end of 4 weeks. Results. When pre-treatment mean signs and symptoms scores were compared in both groups, there was no significant difference (p > 0.05). However, mean post-treatment scores as regards signs and symptoms were found to be lower in cyclosporine group than those in placebo group (p < 0.001). No side effects of the treatment with CsA 0.05% eyedrops were observed. Conclusions. It was found that topical CsA 0.05% eyedrops were safe and effective in the treatment of patients with VKC (Adv Clin Exp Med 2014, 23, 3, 455-461).

show abstract

A Double-Blind Comparison of Efficacy of 0.1% Tacrolimus Ophthalmic Ointment and 2% Cyclosporine Eye Drop Vernal Keratoconjunctivitis (vkc)

Cited by 32 publications

References 0 publications

Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis

Comparative Study of 0.1% Olopatadine vs 0.05% Cyclosporine in Patients of Recalcitrant Vernal Keratoconjunctivitis

Study of Clinical Features and Management of Vernal Keratoconjunctivitis

Topical Cyclosporine A 0.05% Eyedrops in the Treatment of Vernal Keratoconjunctivitis – Randomized Placebo-Controlled Trial

Contact Info

Product

Resources

About